Tango doses first patients in TNG462, TNG260 trials; CSO Alan Huang to depart; Q2 net loss narrows

Tango Therapeutics, Inc.

First patient dosed in phase 1/2 of TNG462 (next-gen PRMT5 inhibitor) for MTAP-deleted tumors.
First patient dosed in phase 1/2 of TNG260 (CoREST inhibitor) with pembrolizumab for STK11-mutant cancers.
CSO Alan Huang to step down Oct 2023; Jannik Andersen promoted to CSO effective Oct 9, 2023.
Cash $310.7M as of June 30, 2023, sufficient to fund operations into 2026.
Q2 2023 net loss $20.7M ($0.23/sh) vs $24.9M ($0.28/sh) in Q2 2022; license revenue $5.0M from Gilead.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alan Huang

Chief Scientific Officer

TNGX · Tango Therapeutics, Inc.

Effective: 2023-10-06
Filed: August 7, 2023, 7:59 PM ET

On August 3, 2023, Alan Huang, Ph.D., the Company's Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tango Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan Huang changed role as Chief Scientific Officer at Tango Therapeutics, Inc..

Action: transition out
Role: Chief Scientific Officer

Exact text from the filing

On August 3, 2023, Alan Huang, Ph.D., the Company's Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-038742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.